201 related articles for article (PubMed ID: 32619652)
1. Design and development of 1,3,5-triazine-thiadiazole hybrids as potent adenosine A
Masih A; Singh S; Agnihotri AK; Giri S; Shrivastava JK; Pandey N; Bhat HR; Singh UP
Neurosci Lett; 2020 Sep; 735():135222. PubMed ID: 32619652
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel 1,3,5-triazine as adenosine A
Masih A; Agnihotri AK; Srivastava JK; Pandey N; Bhat HR; Singh UP
J Biochem Mol Toxicol; 2021 Mar; 35(3):e22659. PubMed ID: 33156955
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of the adenosine A
Sun B; Bachhawat P; Chu ML; Wood M; Ceska T; Sands ZA; Mercier J; Lebon F; Kobilka TS; Kobilka BK
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2066-2071. PubMed ID: 28167788
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent adenosine A2a antagonists as potential anti-Parkinson disease agents. Non-linear QSAR analyses integrated with pharmacophore modeling.
Khanfar MA; Al-Qtaishat S; Habash M; Taha MO
Chem Biol Interact; 2016 Jul; 254():93-101. PubMed ID: 27216633
[TBL] [Abstract][Full Text] [Related]
5. Development of Adenosine A
Zheng J; Zhang X; Zhen X
ACS Chem Neurosci; 2019 Feb; 10(2):783-791. PubMed ID: 30199223
[TBL] [Abstract][Full Text] [Related]
6. Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
Weiss SM; Benwell K; Cliffe IA; Gillespie RJ; Knight AR; Lerpiniere J; Misra A; Pratt RM; Revell D; Upton R; Dourish CT
Neurology; 2003 Dec; 61(11 Suppl 6):S101-6. PubMed ID: 14663021
[TBL] [Abstract][Full Text] [Related]
7. Occupancy of adenosine A
Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation and molecular modelling studies of 1,3,7,8-tetrasubstituted xanthines as potent and selective A
Rohilla S; Bansal R; Kachler S; Klotz KN
Bioorg Chem; 2019 Jun; 87():601-612. PubMed ID: 30933785
[TBL] [Abstract][Full Text] [Related]
9. Novel approaches for targeting the adenosine A2A receptor.
Yuan G; Gedeon NG; Jankins TC; Jones GB
Expert Opin Drug Discov; 2015 Jan; 10(1):63-80. PubMed ID: 25311639
[TBL] [Abstract][Full Text] [Related]
10. Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment.
Shao YM; Ma X; Paira P; Tan A; Herr DR; Lim KL; Ng CH; Venkatesan G; Klotz KN; Federico S; Spalluto G; Cheong SL; Chen YZ; Pastorin G
PLoS One; 2018; 13(1):e0188212. PubMed ID: 29304113
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design.
Congreve M; Andrews SP; Doré AS; Hollenstein K; Hurrell E; Langmead CJ; Mason JS; Ng IW; Tehan B; Zhukov A; Weir M; Marshall FH
J Med Chem; 2012 Mar; 55(5):1898-903. PubMed ID: 22220592
[TBL] [Abstract][Full Text] [Related]
12. Adenosine A
Hagenow S; Affini A; Pioli EY; Hinz S; Zhao Y; Porras G; Namasivayam V; Müller CE; Lin JS; Bezard E; Stark H
J Med Chem; 2021 Jun; 64(12):8246-8262. PubMed ID: 34107215
[TBL] [Abstract][Full Text] [Related]
13. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.
Atack JR; Shook BC; Rassnick S; Jackson PF; Rhodes K; Drinkenburg WH; Ahnaou A; Te Riele P; Langlois X; Hrupka B; De Haes P; Hendrickx H; Aerts N; Hens K; Wellens A; Vermeire J; Megens AA
ACS Chem Neurosci; 2014 Oct; 5(10):1005-19. PubMed ID: 25203719
[TBL] [Abstract][Full Text] [Related]
14. Molecular Basis of Ligand Dissociation from the Adenosine A2A Receptor.
Guo D; Pan AC; Dror RO; Mocking T; Liu R; Heitman LH; Shaw DE; IJzerman AP
Mol Pharmacol; 2016 May; 89(5):485-91. PubMed ID: 26873858
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of (4E)-4-(4-substitutedbenzylideneamino)-3-substituted-2,3-dihydro-2-thioxothiazole-5-carbonitrile as novel A2A receptor antagonists.
Mishra CB; Sharma D; Prakash A; Kumari N; Kumar N; Luthra PM
Bioorg Med Chem; 2013 Oct; 21(19):6077-83. PubMed ID: 23953686
[TBL] [Abstract][Full Text] [Related]
16. Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
Vu CB; Peng B; Kumaravel G; Smits G; Jin X; Phadke D; Engber T; Huang C; Reilly J; Tam S; Grant D; Hetu G; Chen L; Zhang J; Petter RC
J Med Chem; 2004 Aug; 47(17):4291-9. PubMed ID: 15294001
[TBL] [Abstract][Full Text] [Related]
17. Novel adenosine A(2A) receptor ligands: a synthetic, functional and computational investigation of selected literature adenosine A(2A) receptor antagonists for extending into extracellular space.
Jörg M; Shonberg J; Mak FS; Miller ND; Yuriev E; Scammells PJ; Capuano B
Bioorg Med Chem Lett; 2013 Jun; 23(11):3427-33. PubMed ID: 23602401
[TBL] [Abstract][Full Text] [Related]
18. 2-Benzylidene-1-Indanone Analogues as Dual Adenosine A1/A2a Receptor Antagonists for the Potential Treatment of Neurological Conditions.
van Rensburg HJ; Legoabe L; Terre'Blanche G; Van der Walt M
Drug Res (Stuttg); 2019 Jul; 69(7):382-391. PubMed ID: 30616250
[TBL] [Abstract][Full Text] [Related]
19. Targeting the adenosine A
Zhao Y; Zhou YG; Chen JF
Chin J Traumatol; 2024 May; 27(3):125-133. PubMed ID: 37679245
[TBL] [Abstract][Full Text] [Related]
20. Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson's Disease.
Jaiteh M; Zeifman A; Saarinen M; Svenningsson P; Bréa J; Loza MI; Carlsson J
J Med Chem; 2018 Jun; 61(12):5269-5278. PubMed ID: 29792714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
